(Q59349089)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Jennifer Jenks

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Robert F Pass

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

8

Justin Pollara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Tori Huffman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Eduardo Cisneros de la Rosa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Guanhua Xie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Nathan Vandergrift

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sallie R Permar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

language of work or name

English

0 references

publication date

30 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

Proceedings of the National Academy of Sciences of the United States of America

25 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

6267-6272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies

25 March 2020

cites work

1 reference

12 December 2020

Characterization of a major antigenic region on gp55 of human cytomegalovirus

1 reference

12 December 2020

Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus

1 reference

12 December 2020

Distinctive role of IgG1 and IgG3 isotypes in Fc gamma R-mediated functions

1 reference

12 December 2020

Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice

1 reference

12 December 2020

Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures

1 reference

12 December 2020

IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities

1 reference

12 December 2020

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

12 December 2020

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

1 reference

12 December 2020

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

1 reference

12 December 2020

Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells

1 reference

12 December 2020

Congenital cytomegalovirus infection: outcome and diagnosis

1 reference

12 December 2020

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

1 reference

12 December 2020

Human NK cells can control CMV infection in the absence of T cells

1 reference

12 December 2020

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

1 reference

12 December 2020

Impact of expanded newborn screening--United States, 2006.

1 reference

12 December 2020

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

12 December 2020

Vaccine prevention of maternal cytomegalovirus infection

1 reference

12 December 2020

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

1 reference

12 December 2020

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

1 reference

12 December 2020

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

1 reference

12 December 2020

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

1 reference

12 December 2020

License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems

1 reference

12 December 2020

Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis

1 reference

12 December 2020

The "silent" global burden of congenital cytomegalovirus

1 reference

12 December 2020

Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus

1 reference

12 December 2020

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

1 reference

12 December 2020

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

1 reference

12 December 2020

The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

1 reference

12 December 2020

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

1 reference

12 December 2020

Pregnancy and Infection

1 reference

12 December 2020

IgG subclasses and allotypes: from structure to effector functions

1 reference

12 December 2020

The history of vaccination against cytomegalovirus

1 reference

12 December 2020

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

1 reference

12 December 2020

Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.

1 reference

12 December 2020

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

1 reference

12 December 2020

Correction: Crystal Structure of the Human Cytomegalovirus Glycoprotein B.

1 reference

12 December 2020

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

1 reference

12 December 2020

The March towards a Vaccine for Congenital CMV: Rationale and Models

1 reference

12 December 2020

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses

1 reference

12 December 2020

Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector

1 reference

12 December 2020

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.

1 reference

12 December 2020

Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1800177115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29712861%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference